Intravenous colistin sulfate: A rarely used form of polymyxin e for the treatment of severe multidrug-resistant Gram-negative bacterial infections

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 4, 2010, Pages 260-265

  Huang, Jie ^a   Tang, Yao Qing ^a   Sun, Jing Yong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; CREATININE;

ACINETOBACTER BAUMANNII; ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG SAFETY; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY INJURY; KLEBSIELLA PNEUMONIAE; MALE; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANT GRAM NEGATIVE BACTERIA; NONHUMAN; OLIGURIA; PATIENT SELECTION; POSTOPERATIVE INFECTION; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; TRACHEAL ASPIRATION PROCEDURE; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CHINA; COLISTIN; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77949462608     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365540903490018     Document Type: Article

References (25)

1. Fridkin S. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001;29:N64-8.
2. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gramnegative bacterial infections. Clin Infect Dis 2005;40: 1333-1341
3. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
4. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-approved standard M7-A7. Wayne, PA, USA: CLSI; 2006.
5. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-332
6. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICUacquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microb Infect 2005;11:15-21.
7. Ramasubban S, Majumdar A, Das PS. Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock. Indian J Crit Care Med 2008;12: 153-157
8. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hamme SM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gramnegative respiratory tract infections. J Antimicrob Chemother 2004;54:566-569
9. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49:3136-3146
10. Linden P, Kusne S, Coley K, Fontes P, Kramer D, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003;37:E154-60.
11. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-Wittel IM, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenemsusceptible VAP. Clin Infect Dis 2003;36:1111-1118
12. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008;61:417-420
13. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003;7:R78-83.
14. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006;12:1227-1230
15. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICUacquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-121
16. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-1011
17. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007;33:1162-1167
18. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive pro-drug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:1953-1958
19. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53:837-840
20. Colomycin injection [Summary of product characteristics]. Bexley, UK: Forest Laboratories UK Ltd; 2004.
21. Coly-Mycin M Parenteral [package insert]. Bristol, TN, USA: Monarch Pharmaceuticals; 2005.
22. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cystic Fibros 2004;3: 23-28
23. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005;25: 11-25.
24. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-2662
25. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, Tsaganos T, Dontas I, Koutoukas P, et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 2007;29:51-55